
Eleni Bekiari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2382702/publications.pdf Version: 2024-02-01



FIENI REVIADI

#	Article	IF	CITATIONS
1	Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Annals of Internal Medicine, 2013, 159, 262.	3.9	749
2	Complications of Diabetes 2017. Journal of Diabetes Research, 2018, 2018, 1-4.	2.3	307
3	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 361, k1310.	2.3	294
4	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2020, 173, 278-286.	3.9	182
5	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, 2022, 65, 1251-1261.	6.3	93
6	Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 1744-1755.e11.	4.4	84
7	Comparative efficacy of glucoseâ€lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2116-2124.	4.4	79
8	Semaglutide for type 2 diabetes mellitus: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2255-2263.	4.4	71
9	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2021, 174, 108737.	2.8	61
10	Oral semaglutide for type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 335-345.	4.4	54
11	Glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose coâ€transporterâ€2 inhibitors as combination therapy for type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1857-1868.	4.4	44
12	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2016, 52, 458-480.	2.3	42
13	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. Annals of Internal Medicine, 2018, 169, 165.	3.9	38
14	Glucagonâ€like peptideâ€1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 188-193.	4.4	33
15	A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2014, 63, 584-592.	3.4	27
16	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2015, 6, 61-67.	3.2	26
17	Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. Rheumatology International, 2017, 37, 293-298.	3.0	20
18	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy, 2017, 18, 843-851.	1.8	19

Eleni Bekiari

#	Article	IF	CITATIONS
19	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Annals of Gastroenterology, 2018, 31, 572-582.	0.6	19
20	Sotagliflozin for patients with type <scp>2</scp> diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 106-114.	4.4	19
21	Ultraâ€rapidâ€acting insulins for adults with diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2395-2401.	4.4	18
22	Comparative efficacy and safety of glucoseâ€lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 822-831.	4.4	17
23	Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. Endocrine, 2017, 56, 485-494.	2.3	15
24	Eosinophilic pneumonia associated with heroin inhalation: a case report. Wiener Klinische Wochenschrift, 2008, 120, 178-180.	1.9	13
25	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety, 2016, 7, 36-38.	2.4	13
26	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. World Journal of Hepatology, 2018, 10, 595-602.	2.0	12
27	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and metaâ€regression analysis. European Journal of Haematology, 2017, 98, 563-568.	2.2	10
28	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 281-289.	1.9	10
29	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Research and Clinical Practice, 2021, 177, 108921.	2.8	10
30	Insulin sensitivity assessment with euglycemic insulin clamp in adult β-thalassaemia major patients. European Journal of Haematology, 2007, 79, 526-530.	2.2	8
31	Effect of Epinephrine and Insulin Resistance on Human Monocytes Obtained From Lean and Obese Healthy Participants: A Pilot Study. Angiology, 2011, 62, 38-45.	1.8	8
32	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases. Journal of Inflammation Research, 2021, Volume 14, 6893-6906.	3.5	8
33	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. Journal of General Internal Medicine, 2020, , 1.	2.6	7
34	Safety And Efficacy Of 4 Years Of Deferasirox Treatment For Sickle Cell Disease Patients. Hemoglobin, 2013, 37, 94-100.	0.8	6
35	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2549-2557.	2.4	6
36	Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. Anaerobe, 2021, 71, 102441.	2.1	6

Eleni Bekiari

#	Article	IF	CITATIONS
37	Effect of Glucose and Insulin on Oxidized Low-Density Lipoprotein Phagocytosis by Human Monocytes: A Pilot Study. Angiology, 2011, 62, 163-166.	1.8	5
38	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence, 2017, Volume 12, 1-10.	4.7	5
39	Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. Endocrine, 2016, 54, 620-633.	2.3	4
40	Some glucose-lowering drugs reduce risk for major adverse cardiac events. Annals of Internal Medicine, 2020, 173, JC9.	3.9	3
41	Erythrocytosis Secondary to Testosterone Therapy in a Male with Cryptorchidism: A Case Report. International Journal of Gerontology, 2012, 6, 290-291.	0.6	2
42	Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. Diabetes Management, 2015, 5, 119-125.	0.5	2
43	Premixed insulin regimens for type 2 diabetes. Endocrine, 2016, 51, 387-389.	2.3	2
44	Meta-analysis of artificial pancreas trials: methodological considerations. Lancet Diabetes and Endocrinology,the, 2017, 5, 685.	11.4	2
45	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. Annals of Internal Medicine, 2015, 163, 241.	3.9	1
46	In type 2 diabetes, weekly semaglutide reduced HbA _{1c} and increased weight loss more than weekly exenatide ER. Annals of Internal Medicine, 2018, 168, JC46.	3.9	1
47	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2021, 174, 141.	3.9	1
48	KDIGO made 12 recommendations for managing diabetes with CKD. Annals of Internal Medicine, 2021, 174, JC26.	3.9	1
49	Hemosiderosis and diabetes mellitus in an untransfused patient with hemoglobin H disease and H63D homozygous hereditary hemochromatosis. Diabetes Research and Clinical Practice, 2007, 76, 468-469.	2.8	0
50	Most add-on therapies to metformin have similar effects on HbA1c. Evidence-Based Medicine, 2016, 21, 223-223.	0.6	0
51	Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	0
52	In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors. Annals of Internal Medicine, 2020, 173, JC70.	3.9	0